Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability
Subramania Nainar Meyyanathan.
Olanzapine, a lipophilic antipsychotic drug, has poor oral bioavailability due to hepatic first-pass metabolism. Solid Lipid
Nanoparticles (SLNs) of Olanzapine were developed using lipids (Stearic acid and Glyceryl monostearate), soy lecithin, poloxamer 188
and charge modifier stearyl amine by microemulsion technique. The aim of this research was to find out whether the bioavailability of
olanzapine can be improved by administering olanzapine SLN orally to Wistar rats. Area under curve was increased (up to 4-fold) and
clearance was decreased when olanzapine entrapped in SLNs with stearylamine were administered orally compared with that of olanzapine
suspension. The enhanced relative bioavailability by the SLNs formulation might be attributed to avoidance of first-pass hepatic metabolism
by intestinal lymphatic transport, direct uptake of nanoparticles through the GI tract, increased permeability by surfactants, and
decreased degradation and clearance. These results indicate that olanzapine can be loaded into solid lipid nanoparticles for improvement
of its oral bioavailability.
Keywords: Bioavailability, cationic, microemulsion, olanzapine, oral delivery, solid lipid nanoparticles
Rights & PermissionsPrintExport